journal
MENU ▼
Read by QxMD icon Read
search

Advances in Therapy

journal
https://read.qxmd.com/read/30980281/anti-mek-and-anti-egfr-mabs-in-ras-mutant-metastatic-colorectal-cancer-case-series-and-rationale
#1
Fanny Ledys, Valentin Derangère, Manon Réda, Jean-Florian Guion, Romily Milliex, Valérie Roux, Emeric Limagne, Laurent Arnould, Leila Bengrine, François Ghiringhelli, Cédric Rébé
KRAS (Kirsten rat sarcoma viral oncogene) or BRAF (v-raf murine sarcoma viral oncogene homolog B1) constitutive activation leads to anti-EGFR (epidermal growth factor receptor) therapy resistance of metastatic colorectal cancer patients. In this article we investigate the effects of anti-MEK (mitogen-activated protein kinase) antibody (trametinib) combined with anti-EGFR (cetuximab) on colon cancer cell lines with different RAS statuses. Even though cetuximab has no effect on RAS cell viability and ERK (extracellular-signal-regulated kinase) phosphorylation (one of the last kinases of the EGFR pathway), trametinib can induce cell death and inhibit the activation of ERK alone or in combination with cetuximab...
April 12, 2019: Advances in Therapy
https://read.qxmd.com/read/30980280/correction-to-a-relative-cost-of-control-analysis-of-once-weekly-semaglutide-versus-exenatide-extended-release-and-dulaglutide-for-bringing-patients-to-hba1c-and-weight-loss-treatment-targets-in-the-usa
#2
Pierre Johansen, Barnaby Hunt, Neeraj N Iyer, Tam Dang-Tan, Richard F Pollock
The article "A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA", written by Pierre Johansen, Barnaby Hunt, Neeraj N. Iyer, Tam Dang-Tan, Richard F. Pollock was originally published electronically on the publisher's internet portal (currently SpringerLink) on November 27, 2018 without Open Access.
April 12, 2019: Advances in Therapy
https://read.qxmd.com/read/30972657/gender-effects-in-the-efficacy-of-racemic-amphetamine-sulfate-in-children-with-attention-deficit-hyperactivity-disorder
#3
Ann C Childress, Jeffrey H Newcorn, Andrew J Cutler
INTRODUCTION: A laboratory classroom study in children aged 6-12 years with attention-deficit/hyperactivity disorder (ADHD) found that racemic amphetamine sulfate (RA-AMPH) significantly improved performance versus placebo from 45 min through 10 h post-dose (NCT01986062). A secondary analysis assessed gender as a potential moderator of response to treatment comparing the ADHD Rating Scale-IV (ADHD-RS-IV) and Swanson, Kotkin, Agler, M-Flynn and Pelham (SKAMP) rating scales. METHODS: After 8 weeks of open-label RA-AMPH dose optimization using improvement in ADHD-RS-IV symptoms as a guide, 97 subjects (38 females and 59 males) were randomized to the sequence of 2 weeks of double-blind treatment with the optimized dose of RA-AMPH followed by placebo or vice versa during a laboratory classroom day...
April 10, 2019: Advances in Therapy
https://read.qxmd.com/read/30972656/comparison-of-doppler-guided-transanal-hemorrhoidal-dearterialization-for-grade-iii-and-iv-hemorrhoids-in-vietnam
#4
Le Manh Cuong, Tran Thu Ha, Nguyen Ngoc Anh, Nguyen Tien Thanh, Vu Duy Kien, Nguyen Duc Lam
INTRODUCTION: This study aimed to assess the short- and long-term outcomes of Doppler-guided transanal hemorrhoidal dearterialization (THD) for grade III and IV hemorrhoidal disease in Vietnam. METHODS: In a prospective observational design, patients treated for grade III and IV hemorrhoidal disease with the THD method at the National Hospital of Traditional Medicine (Hanoi, Vietnam) were included between June 2012 and December 2013. Patients were evaluated postoperatively at the time they were discharged from the hospital (short-term outcome) and 6 months after surgery (long-term outcome)...
April 10, 2019: Advances in Therapy
https://read.qxmd.com/read/30968336/efficacy-of-triamcinolone-acetonide-extended-release-in-participants-with-unilateral-knee-osteoarthritis-a-post-hoc-analysis
#5
Michael J Langworthy, Philip G Conaghan, Joseph J Ruane, Alan J Kivitz, Joelle Lufkin, Amy Cinar, Scott D Kelley
INTRODUCTION: Osteoarthritis (OA) is common and its prevalence is increased in military service members. In a phase 3 randomized controlled trial (NCT02357459), a single intra-articular injection of an extended-release formulation of triamcinolone acetonide (TA-ER) in participants with unilateral or bilateral knee OA demonstrated substantial improvement in pain and symptoms. Bilateral knee pain has emerged as a confounding factor in clinical trials when evaluating the effect of a single intra-articular injection...
April 9, 2019: Advances in Therapy
https://read.qxmd.com/read/30963514/indirect-comparison-of-ropinirole-and-pramipexole-as-levodopa-adjunctive-therapy-in-advanced-parkinson-s-disease-a-systematic-review-and-network-meta-analysis
#6
REVIEW
Hongxin Zhao, Yi Ning, James Cooper, Rodrigo Refoios Camejo, Xiajun Ni, Bingming Yi, Daniel Parks
INTRODUCTION: To evaluate the comparative efficacy and safety of ropinirole and pramipexole as adjunctive therapies to levodopa (L-dopa) for the management of advanced Parkinson's disease (PD), via a systematic review and network meta-analysis. METHODS: Twenty-one double-blind randomised controlled trials of patients with advanced PD with motor fluctuations receiving L-dopa comparing ropinirole or pramipexole with comparators were identified from 2550 publications...
April 8, 2019: Advances in Therapy
https://read.qxmd.com/read/30963513/outcomes-associated-with-treatment-of-chronic-pain-with-tapentadol-compared-with-morphine-and-oxycodone-a-uk-primary-care-observational-study
#7
Christopher Ll Morgan, Sara Jenkins-Jones, Craig Currie, Garth Baxter
INTRODUCTION: This study compared adverse outcomes and resource use for patients with a diagnosis of pain treated with tapentadol prolonged-release (PR) versus those treated with morphine controlled-release (CR) and oxycodone CR. METHODS: Data were sourced from the Clinical Practice Research Datalink (CPRD), a database derived from UK primary care. Patients prescribed tapentadol PR between May 2011 and December 2016 were selected and matched to two groups of controls treated with either morphine CR or oxycodone CR on gender, age, pain duration, pain site, pain aetiology, Charlson index and prior analgesia...
April 8, 2019: Advances in Therapy
https://read.qxmd.com/read/30963512/observational-prospective-study-to-determine-the-evolution-of-the-symptomatic-profile-of-metastatic-non-small-cell-lung-cancer-nsclc-patients-and-its-relation-to-the-control-of-the-disease
#8
Manuel Dómine, Bartomeu Massuti, Javier Puente, Antonio Calles, Emilio Esteban, Eduardo Triguboff, Yashmin Silvana Afonzo, Regina Gironés, Francisco Aparisi, Juana Oramas
OBJECTIVE: To evaluate the evolution of disease-related symptoms and its relationship with the control of the disease in first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC). METHODS: This was an observational, prospective, national and multicentre study with two visits in which the following were collected: (1) baseline visit: sociodemographic and clinical variables (2) visit after completing the 4-6 chemotherapy cycles: criteria for ending treatment, control of the disease and clinical variables...
April 8, 2019: Advances in Therapy
https://read.qxmd.com/read/30953333/roxadustat-treatment-of-chronic-kidney-disease-associated-anemia-in-japanese-patients-not-on-dialysis-a-phase-2-randomized-double-blind-placebo-controlled-trial
#9
Tadao Akizawa, Manabu Iwasaki, Tetsuro Otsuka, Michael Reusch, Toshihiro Misumi
INTRODUCTION: This study evaluated efficacy and safety/tolerability of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, in Japanese anemic non-dialysis-dependent chronic kidney disease (NDD-CKD) patients. METHODS: In this phase 2, double-blind, 24-week study, NDD-CKD patients were randomized to oral placebo or roxadustat (50, 70, or 100 mg) three times weekly (TIW) for 6 weeks followed by dose adjustments to maintain hemoglobin (Hb) at 10-12 g/dL for 18 weeks; patients meeting pre-defined criteria were re-randomized to TIW or once-weekly dosing...
April 5, 2019: Advances in Therapy
https://read.qxmd.com/read/30953332/metastatic-renal-cell-cancer-an-analysis-of-reimbursement-decisions
#10
REVIEW
Carina Schey, Genevieve Meier, Janice Pan
INTRODUCTION: Metastatic renal cell carcinoma is a complex cancer for which several drugs have been developed over the years. More recently, drugs that target the specific cancer cell mutations have been developed for metastatic cell carcinoma. However, even with the recent influx of targeted therapy options, significant unmet needs exist in around half of treated renal cell carcinoma patients following the failure of first-line therapy. The aim of this study was to review the health technology appraisals of renal cell carcinoma treatments in several countries to establish what factors might affect the reimbursement decisions...
April 5, 2019: Advances in Therapy
https://read.qxmd.com/read/30953331/prevalence-and-control-of-dyslipidemia-in-patients-referred-for-high-blood-pressure-the-disregarded-double-trouble-lipid-profile-in-overweight-obese
#11
Francesco Spannella, Federico Giulietti, Chiara Di Pentima, Riccardo Sarzani
INTRODUCTION: We evaluated the prevalence and control of dyslipidemia in a wide sample of patients referred to our ESH "Hypertension Excellence Centre" for high blood pressure (BP). Furthermore, we evaluated the role of adiposity on the serum lipid profile. METHODS: Observational study on 1219 consecutive outpatients with valid ambulatory BP monitoring (ABPM) referred for high BP. Patients with body mass index (BMI) ≥ 25 kg/m2 were defined as overweight/obese (OW/OB)...
April 5, 2019: Advances in Therapy
https://read.qxmd.com/read/30953330/a-48-week-multicenter-open-label-observational-study-evaluating-oral-rivastigmine-in-patients-with-mild-to-moderate-alzheimer-s-disease-in-taiwan
#12
Chiung-Chih Chang, Giia-Sheun Peng, Te-Jen Lai, Chien-Hsun Li, Ching-Kuan Liu
INTRODUCTION: Rivastigmine is a cholinesterase inhibitor, approved for the treatment of mild-to-moderate dementia of Alzheimer's type. This study assessed the short- and long-term effectiveness and safety of rivastigmine in patients with mild-to-moderate Alzheimer's disease (AD) in a real-world clinical setting in Taiwan. METHODS: This was a 48-week, single-arm, open-label, prospective, observational, post-marketing surveillance, multicenter study. The primary outcomes were change from baseline to week 48 in the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) scores...
April 5, 2019: Advances in Therapy
https://read.qxmd.com/read/30941724/real-world-study-of-once-daily-extended-release-tacrolimus-versus-twice-daily-immediate-release-tacrolimus-in-kidney-transplantation-clinical-outcomes-and-healthcare-resource-utilization
#13
Bing Ho, Hardik Bhagat, Jason J Schwartz, Kofi Atiemo, Amna Daud, Raymond Kang, Samantha E Montag, Lihui Zhao, Edward Lee, Anton I Skaro, Daniela P Ladner
INTRODUCTION: Real-world data with extended-release tacrolimus (ER-T) are lacking in the USA. This study examined clinical outcomes and healthcare resource utilization in kidney transplant patients receiving ER-T in clinical practice. METHODS: This was a retrospective, single-center analysis (February-June 2016) using data from Northwestern University's Enterprise Data Warehouse. Adult patients receiving a kidney transplant in the preceding 4 years, treated de novo or converted to ER-T from immediate-release tacrolimus (IR-T) within 10 days post-transplantation, and maintained on ER-T (at least 3 months) were included...
April 2, 2019: Advances in Therapy
https://read.qxmd.com/read/30941723/integrating-osimertinib-in-clinical-practice-for-non-small-cell-lung-cancer-treatment
#14
REVIEW
Senthil Rajappa, M Vamshi Krishna, Prasad Narayanan
Treatment of non-small cell lung cancer (NSCLC) is evolving with the use of precision medicine for patients with sensitizing epidermal growth factor receptor (EGFR) mutation. First- and second-generation EGFR tyrosine kinase inhibitors (TKIs) remained the standard of care for patients with EGFR-mutated advanced NSCLC for about a decade. However, treatment resistance eventually develops for most patients who experience initial response to these agents. The most commonly acquired resistance mechanism is the T790M gatekeeper mutation...
April 2, 2019: Advances in Therapy
https://read.qxmd.com/read/30941722/a-multicenter-observational-prospective-study-of-the-effectiveness-of-switching-from-budesonide-formoterol-turbuhaler-%C3%A2-to-budesonide-formoterol-easyhaler-%C3%A2
#15
Jörgen Syk, Ines Vinge, Mikael Sörberg, Mikko Vahteristo, Paula Rytilä
INTRODUCTION: In real-life practice, asthma remains poorly controlled, with a considerable burden on patients' quality of life. Budesonide/formoterol (B/F) Easyhaler® has demonstrated similar dose consistency, therapeutic equivalence, and equivalent bronchodilator efficacy to B/F Turbuhaler® , but no real-life comparisons are yet available in patients switching from B/F Turbuhaler® to B/F Easyhaler® . METHODS: The primary objective of this real-life, non-interventional, observational study was to show non-inferiority of asthma control when adult patients in Swedish primary care with persistent asthma switched from B/F Turbuhaler® to B/F Easyhaler® ...
April 2, 2019: Advances in Therapy
https://read.qxmd.com/read/30929187/response-to-a-rigorous-evaluation-of-methoxyflurane-is-needed-comment-on-methoxyflurane-versus-standard-of-care-for-acute-trauma-related-pain-in-the-emergency-setting-protocol-for-a-randomised-controlled-study-in-italy-medita
#16
LETTER
Andrea Fabbri, Giuseppe Carpinteri, Germana Ruggiano, Elisabetta Bonafede, Antonella Sblendido, Alberto Farina, Amedeo Soldi
No abstract text is available yet for this article.
March 30, 2019: Advances in Therapy
https://read.qxmd.com/read/30929186/a-rigorous-evaluation-of-methoxyflurane-is-needed-comment-on-methoxyflurane-versus-standard-of-care-for-acute-trauma-related-pain-in-the-emergency-setting-protocol-for-a-randomised-controlled-study-in-italy-medita
#17
LETTER
https://read.qxmd.com/read/30929185/differentiating-basal-insulin-preparations-understanding-how-they-work-explains-why-they-are-different
#18
REVIEW
Alice Y Y Cheng, Dhiren K Patel, Timothy S Reid, Kathleen Wyne
Since the introduction of insulin as a life-saving agent for patients with type 1 diabetes, insulin preparations have evolved to approximate physiologic insulin delivery profiles to meet prandial and basal insulin needs. While prandial insulins are designed to have quick time-action profiles that minimize postprandial glucose excursions, basal insulins are designed to have a protracted time-action profile to facilitate basal glucose control over 24 h. Given that all insulins have the same mechanism of action at the target tissue level, the differences in time-action profiles are achieved through different mechanisms of protraction, resulting in different behaviors in the subcutaneous space and different rates of absorption into the circulation...
March 30, 2019: Advances in Therapy
https://read.qxmd.com/read/30929184/economic-burden-of-illness-among-commercially-insured-patients-with-systemic-sclerosis-with-interstitial-lung-disease-in-the-usa-a-claims-data-analysis
#19
Zhou Zhou, Yanni Fan, Darren Thomason, Wenxi Tang, Xinyue Liu, Zheng-Yi Zhou, Dendy Macaulay, Aryeh Fischer
INTRODUCTION: Interstitial lung disease (ILD) is a common manifestation of scleroderma/systemic sclerosis (SSc). However, the direct and indirect economic burdens of SSc-ILD remain unclear. This study assessed and compared healthcare resource utilization (HRU), direct healthcare costs, work loss, and indirect costs between patients with SSc-ILD and matched controls with neither SSc nor ILD in the USA. METHODS: Data were obtained from a large US commercial claims database (2005-2015)...
March 30, 2019: Advances in Therapy
https://read.qxmd.com/read/30915658/response-letter-addressing-letter-to-the-editor-regarding-gottschlich-s-r%C3%A3-schmann-k-candler-h-adv-ther-2018-35-1023-1034-doi-10-1007-s12325-018-0736-7
#20
LETTER
Stefan Gottschlich, Kristina Röschmann, Henning Candler
No abstract text is available yet for this article.
March 26, 2019: Advances in Therapy
journal
journal
29381
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"